Spago Nanomedical
0.334 SEK -14.8%Be the first to follow this company
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SPAGO
Daily low / high price
0.322 / 0.388
SEK
Market cap
116.3M SEK
Turnover
165.51K SEK
Volume
480K
Financial calendar
Interim report
2024-08-21
Interim report
2024-11-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Peter Lindell | 40.5 % | 40.5 % |
Mikael Lönn | 8.5 % | 8.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB
Penser Access by Carnegie: Spago Nanomedical: Hög nyttjandegrad av teckningsoptioner
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools